Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDIO NASDAQ:NEUP NASDAQ:NRSN NASDAQ:PLRZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDIOCardio Diagnostics$1.96-7.1%$1.85$0.97▼$7.91$5.80M2.2472,812 shs64,763 shsNEUPNeuphoria Therapeutics$4.49-7.2%$4.88$3.64▼$21.40$24.27M0.7256,749 shs82,567 shsNRSNNeuroSense Therapeutics$0.75-3.8%$0.79$0.63▼$2.60$24.42M1.56101,066 shs102,135 shsPLRZPolyrizon$12.99+1.5%$13.75$2.88▼$18.20$24.31M-1.939,210 shs48,221 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDIOCardio Diagnostics-7.11%+3.70%+7.69%-63.02%-60.72%NEUPNeuphoria Therapeutics-7.23%-15.44%-16.54%+3.94%-37.20%NRSNNeuroSense Therapeutics-3.85%-8.68%-16.46%-13.38%-55.88%PLRZPolyrizon+1.48%-24.34%-9.41%-0.92%+143.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDIOCardio Diagnostics$1.96-7.1%$1.85$0.97▼$7.91$5.80M2.2472,812 shs64,763 shsNEUPNeuphoria Therapeutics$4.49-7.2%$4.88$3.64▼$21.40$24.27M0.7256,749 shs82,567 shsNRSNNeuroSense Therapeutics$0.75-3.8%$0.79$0.63▼$2.60$24.42M1.56101,066 shs102,135 shsPLRZPolyrizon$12.99+1.5%$13.75$2.88▼$18.20$24.31M-1.939,210 shs48,221 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDIOCardio Diagnostics-7.11%+3.70%+7.69%-63.02%-60.72%NEUPNeuphoria Therapeutics-7.23%-15.44%-16.54%+3.94%-37.20%NRSNNeuroSense Therapeutics-3.85%-8.68%-16.46%-13.38%-55.88%PLRZPolyrizon+1.48%-24.34%-9.41%-0.92%+143.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDIOCardio Diagnostics 1.00SellN/AN/ANEUPNeuphoria Therapeutics 2.00Hold$21.00367.71% UpsideNRSNNeuroSense Therapeutics 2.60Moderate Buy$8.501,033.18% UpsidePLRZPolyrizon 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest CDIO, NRSN, PLRZ, and NEUP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026NEUPNeuphoria Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/21/2026PLRZPolyrizon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026NEUPNeuphoria Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral5/8/2026NRSNNeuroSense Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/4/2026PLRZPolyrizon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026NRSNNeuroSense Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.003/25/2026NRSNNeuroSense Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.003/17/2026NRSNNeuroSense Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.003/10/2026NRSNNeuroSense Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$3.003/9/2026NRSNNeuroSense Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.00(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDIOCardio Diagnostics$10K580.16N/AN/A$3.82 per share0.51NEUPNeuphoria Therapeutics$15.65M1.55$0.16 per share28.81$10.11 per share0.44NRSNNeuroSense TherapeuticsN/AN/AN/AN/A($0.05) per shareN/APLRZPolyrizonN/AN/AN/AN/A$13.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDIOCardio Diagnostics-$6.50M-$3.38N/AN/AN/A-36,950.00%-78.82%-72.87%8/13/2026 (Estimated)NEUPNeuphoria Therapeutics-$370K-$11.06N/AN/AN/AN/A-76.93%-54.76%N/ANRSNNeuroSense Therapeutics-$11.12M-$0.54N/AN/AN/AN/AN/AN/A6/22/2026 (Estimated)PLRZPolyrizon-$3.34MN/AN/AN/AN/AN/AN/AN/AN/ALatest CDIO, NRSN, PLRZ, and NEUP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/30/2026N/ANRSNNeuroSense Therapeutics-$0.1950N/AN/AN/A$0.27 millionN/A5/15/2026Q1 2026CDIOCardio DiagnosticsN/A-$0.63N/A-$0.63N/AN/A5/15/2026Q3 2026NEUPNeuphoria Therapeutics-$0.56-$0.09+$0.47-$0.09N/AN/A3/25/2026Q4 2025PLRZPolyrizonN/A$2.81N/A-$2.81N/AN/A3/13/2026Q4 2025CDIOCardio DiagnosticsN/A-$0.80N/A-$0.80N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCDIOCardio DiagnosticsN/AN/AN/AN/AN/ANEUPNeuphoria TherapeuticsN/AN/AN/AN/AN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDIOCardio DiagnosticsN/A15.7715.77NEUPNeuphoria TherapeuticsN/A14.3114.31NRSNNeuroSense TherapeuticsN/A0.310.31PLRZPolyrizonN/A29.0329.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDIOCardio Diagnostics8.06%NEUPNeuphoria Therapeutics15.90%NRSNNeuroSense Therapeutics1.04%PLRZPolyrizonN/AInsider OwnershipCompanyInsider OwnershipCDIOCardio Diagnostics13.30%NEUPNeuphoria Therapeutics1.50%NRSNNeuroSense Therapeutics27.40%PLRZPolyrizonN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDIOCardio Diagnostics12.96 million2.57 millionNot OptionableNEUPNeuphoria TherapeuticsN/A5.40 million5.32 millionN/ANRSNNeuroSense Therapeutics1032.56 million23.64 millionNot OptionablePLRZPolyrizonN/A1.87 millionN/AN/ACDIO, NRSN, PLRZ, and NEUP HeadlinesRecent News About These CompaniesPolyrizon Extends Exclusivity on Proposed 51% Acquisition of Arrow AviationJune 5 at 4:31 PM | tipranks.comPolyrizon (NASDAQ:PLRZ) Cut to "Sell" at Wall Street ZenMay 30, 2026 | americanbankingnews.comPolyrizon Appoints Veteran Entrepreneur Ami Oren to Board of DirectorsMay 27, 2026 | tipranks.comPolyrizon Stock Short Interest Report | NASDAQ:PLRZ | BenzingaMay 16, 2026 | benzinga.comPolyrizon Secures First U.S. Clinical Site for NASARIX Allergy Blocker TrialMay 13, 2026 | tipranks.comPolyrizon Ltd. Signs Clinical Trial Agreement for NASARIXTM Allergy Blocker Study in TexasMay 13, 2026 | quiverquant.comQPolyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical TrialMay 13, 2026 | globenewswire.comPulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable ProtectionMay 11, 2026 | prnewswire.comPolyrizon Expands U.S. Patent Claims for Intranasal Drug Delivery PlatformMay 4, 2026 | tipranks.comPolyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery PlatformMay 4, 2026 | globenewswire.comPolyrizon Ltd. Files Divisional Patent Application for Advanced Trap & Target Intranasal Drug Delivery TechnologyApril 27, 2026 | quiverquant.comQPolyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery PlatformApril 27, 2026 | globenewswire.comPLRZ Share News TodayApril 19, 2026 | uk.investing.comPolyrizon Raises $3.5 Million via Registered Direct Offering and Private PlacementApril 14, 2026 | theglobeandmail.comPolyrizon Ltd. Ordinary Shares (PLRZ) Institutional HoldingsApril 8, 2026 | nasdaq.comPolyrizon Ltd. Completes $3.5 Million Registered Direct Offering and Private PlacementApril 8, 2026 | quiverquant.comQPolyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private PlacementsApril 8, 2026 | globenewswire.comPolyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private PlacementApril 7, 2026 | finance.yahoo.comPolyrizon Ltd. Ordinary Shares (PLRZ) Option ChainMarch 29, 2026 | nasdaq.comPolyrizon Ltd. Ordinary Shares (PLRZ) Insider ActivityMarch 28, 2026 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCDIO, NRSN, PLRZ, and NEUP Company DescriptionsCardio Diagnostics NASDAQ:CDIO$1.96 -0.15 (-7.11%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$2.05 +0.09 (+4.39%) As of 06/5/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.Neuphoria Therapeutics NASDAQ:NEUP$4.49 -0.35 (-7.23%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$4.48 -0.01 (-0.22%) As of 06/5/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.NeuroSense Therapeutics NASDAQ:NRSN$0.75 -0.03 (-3.85%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$0.75 0.00 (-0.01%) As of 06/5/2026 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.Polyrizon NASDAQ:PLRZ$12.99 +0.19 (+1.48%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$12.14 -0.85 (-6.51%) As of 06/5/2026 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
